Smith L, Will A M, Williams R F, Stevens R F
Department of Paediatric Oncology, Royal Manchester Children's Hospital, U.K.
J Infect. 1990 May;20(3):201-6. doi: 10.1016/0163-4453(90)91019-a.
Efficacy of the cephalosporin, ceftriaxone, was compared with that of the combination of the aminoglycoside, netilmicin, and the penicillin, azlocillin, in the treatment of febrile episodes in immunocompromised neutropenic children undergoing chemotherapy for neoplastic disease. During 100 separate febrile episodes, 40 strains of bacteria were isolated from the blood of 34 patients and a further 55 strains from other sites. Nine strains (four of which were staphylococci) to both netilmicin and azlocillin. There was no difference in clinical response between the two therapeutic regimens as assessed 4 and 7 days after treatment began. Ceftriaxone had the considerable practical advantages of once daily dosage without a need for blood monitoring. Ceftriaxone would appear to be effective as initial monotherapy in the treatment of bacterial infections in severely neutropenic children.
在接受肿瘤疾病化疗的免疫功能低下的中性粒细胞减少儿童发热性疾病的治疗中，对头孢菌素头孢曲松与氨基糖苷类药物奈替米星和青霉素阿洛西林联合用药的疗效进行了比较。在100次单独的发热性疾病发作期间，从34例患者的血液中分离出40株细菌，从其他部位又分离出55株。有9株（其中4株为葡萄球菌）对奈替米星和阿洛西林均耐药。在治疗开始后4天和7天评估时，两种治疗方案的临床反应没有差异。头孢曲松具有每日给药一次且无需进行血液监测的显著实际优势。头孢曲松似乎可作为严重中性粒细胞减少儿童细菌感染治疗的初始单一疗法有效。
